drugset
drugset / Trial / NCT00472693

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

NCT00472693 ↗

Phase 2 Completed 5 enrolled Abramson Cancer Center at Penn Medicine Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.

Timeline

Start
2007-05
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abraxane Small molecule 100 mg/m2 Intravenous
Subject Bevacizumab Monoclonal antibody 10 mg/m2 Intravenous

Indications

breast cancer